Coca Cola KO stock analysis and is KO stock a good investment

Rock­et Phar­ma­ceu­ti­cals re­port­ed Mon­day that ben­e­fits from its Danon dis­ease gene ther­a­py were seen up to around five years af­ter treat­ment. The Cran­bury, NJ-based biotech

An­nex­on Bio­sciences re­port­ed new Phase 3 da­ta for its Guil­lain-Bar­ré Syn­drome (GBS) drug Tues­day morn­ing, say­ing the low dose achieved the tri­al’s pri­ma­ry end­point. …

Mer­ck’s megablock­buster can­cer drug Keytru­da (pem­brolizum­ab) won a high­ly sought-af­ter FDA ap­proval as the first check­point in­hibitor to treat pa­tients with ear­ly-stage non-small cell lung